We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Deal watch: Roche deal targets glutamate in neurodevelopmental disorders.
- Authors
Harrison, Charlotte
- Abstract
The article reports on the agreement between Seaside Therapeutics Inc. and Roche for the treatment of Fragile X syndrome (FXS) and autism spectrum disorders (ASD). It says that the collaboration will focus on the antagonists of metabolic glutamate receptor 5 (mGluR5) and agonists of gamma-aminobutyric acid type B (GABA) receptors. It also mentions that Seaside will license the patents on the use of mGluR5 antagonist for Roche.
- Subjects
BUSINESS partnerships; FRAGILE X syndrome; TREATMENT of developmental disabilities; AUTISM spectrum disorders; MODELS (Patents); F. Hoffmann-La Roche Ltd.; SEASIDE Therapeutics Inc.; THERAPEUTICS
- Publication
Nature Reviews Drug Discovery, 2012, Vol 11, Issue 8, p590
- ISSN
1474-1776
- Publication type
Article
- DOI
10.1038/nrd3808